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Abstract
Dexmedetomidine is a highly speciﬁc, potent and selective a2-adrenoceptor agonist. Although intrathecal and epidural administration
of dexmedetomidine has been found to produce analgesia, whether this analgesia results from an effect on spinal cord substantia
gelatinosa (SG) neurons remains unclear. Here, we investigated the effects of dexmedetomidine on postsynaptic transmission in SG
neurons of rat spinal cord slices using the whole-cell patch-clamp technique. In 92% of the SG neurons examined (n = 84), bath-
applied dexmedetomidine induced outward currents at )70 mV in a concentration-dependent manner, with the value of effective
concentration producing a half-maximal response (0.62 lm). The outward currents induced by dexmedetomidine were suppressed by
the a2-adrenoceptor antagonist yohimbine, but not by prazosin, an a1-, a2B- and a2C-adrenoceptor antagonist. Moreover, the
dexmedetomidine-induced currents were partially suppressed by the a2C-adrenoceptor antagonist JP-1302, while simultaneous
application of JP-1302 and the a2A-adrenoceptor antagonist BRL44408 abolished the current completely. The action of
dexmedetomidine was mimicked by the a2A-adrenoceptor agonist oxymetazoline. Plots of the current–voltage relationship revealed
a reversal potential at around )86 mV. Dexmedetomidine-induced currents were blocked by the addition of GDP-b-S [guanosine-
5¢-O-(2-thiodiphosphate)] or Cs
+ to the pipette solution. These ﬁndings suggest that dexmedetomidine hyperpolarizes the membrane
potentials of SG neurons by G-protein-mediated activation of K
+ channels through a2A- and a2C-adrenoceptors. This action of
dexmedetomidine might contribute, at least in part, to its antinociceptive action in the spinal cord.
Introduction
a2-Adrenoceptor agonists mediate a number of physiological phe-
nomena such as antinociception (Yaksh, 1985). They produce an
antinociceptive effect by action on the locus ceruleus (Guo et al.,
1996) and spinal cord (Yaksh, 1985; Takano & Yaksh, 1991).
Clonidine was the ﬁrst a2-adrenoceptor agonist to be introduced
clinically. It has analgesic properties when given epidurally or
intrathecally in humans. Epidural clonidine was found to be effective
in reducing both postoperative pain (Anzai & Nishikawa, 1995) and
intractable neuropathic cancer pain (Eisenach et al., 1995). Intrathecal
clonidine also decreased postoperative pain (Filos et al., 1994).
Dexmedetomidine is another a2-adrenoceptor agonist. Intravenous
administration of dexmedetomidine has been used clinically for
sedation in the intensive care unit (Venn & Grounds, 2001).
Meanwhile, several lines of evidence indicate that administration of
dexmedetomidine produces spinal analgesia as efﬁciently as clonidine.
Behavioral studies in rats have demonstrated an inhibition of
nociceptive responses by intrathecally (Fisher et al., 1991) and
epidurally (Asano et al., 2000) administered dexmedetomidine.
a2-Adrenoceptor agonists are also used in as adjuncts to general
anesthesia. The effect of oral clonidine premedication can reduce
volatile anesthetic (Ghignone et al., 1987) and opioid (Ghignone et al.,
1986) requirements in the perioperative period. Intravenous adminis-
tration of dexmedetomidine similarly diminishes the volatile anes-
thetic (Aho et al., 1992) and opioid (But et al., 2006) requirements.
Although both clonidine and dexmedetomidine are a2-adrenoceptor
agonists, several differences exist between the two. First, the potency
of dexmedetomidine is much greater than that of clonidine at maxi-
mum efﬁcacy. Intraperitoneal administration of clonidine decreased
minimum alveolar concentration, which produces immobility in 50%
of subjects exposed to a noxious stimulus, for halothane about 40% in
rats, whereas minimum alveolar concentration was decreased about
90% by dexmedetomidine (Maze et al., 1987; Segal et al., 1988). A
second difference lies in the relative a2⁄a1 selectivity ratio. The
a2⁄a1-adrenoceptor selectivity ratio of clonidine is 220 : 1 (Virtanen
et al., 1988). Accordingly, high doses of clonidine may induce
cardiovascular side-effects via the a1-adrenoceptor (Virtanen et al.,
1988). The a2-⁄a1-adrenoceptor selectivity ratio of dexmedetomidine
is 1620 : 1 (Virtanen et al., 1988). As dexmedetomidine is a highly
selective a2-adrenoceptor agonist (Savola & Virtanen, 1991), dex-
medetomidine causes fewer side-effects mediated by a1-adrenoceptor
activation than clonidine.
Neurons of the superﬁcial dorsal horn, especially lamina II
(substantia gelatinosa: SG), are thought to play an important role in
modulating nociceptive transmission, because they preferentially
receive thin myelinated Ad- and unmyelinated C-primary afferent
ﬁbers, both of which carry nociceptive information from the periphery
(Kumazawa & Perl, 1978; Yoshimura & Jessell, 1989). Moreover,
binding and immunohistochemical studies show that the highest
density of a2-adrenoceptors is in the superﬁcial layers of the spinal
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dexmedetomidine exerts its effect on SG neurons remains unclear. In
the present study, we used whole-cell patch-clamp recording to clarify
whether dexmedetomidine has postsynaptic effects on SG neurons and
to conﬁrm the involvement of a2-adrenoceptors.
Materials and methods
ThisstudywasapprovedbytheAnimalResearchCommittee ofNiigata
University Graduate School of Medical and Dental Sciences in Niigata,
Japan. All efforts were made to minimize the number of animals used.
Spinal cord slice preparation
Male Wistar rats (4–8 weeks old) were anesthetized with urethane
(1.5 g⁄kg, i.p.). The lumbosacral segment of the spinal cord was
removed as described previously (Yoshimura & Nishi, 1993; Kohno
et al., 2003) and placed in a preoxygenated ice-cold (1–3 C) sucrose-
substituted Krebs solution containing (in mm): KCl 6.4, MgSO4 4.1,
NaHCO3 26, NaH2PO4 1.3, glucose 10 and sucrose 252, bubbled with
95% O2 and 5% CO2 (Wang et al., 1999). Transverse spinal cord
slices (500 lm) were cut on a vibrating microslicer. The slices were
placed on a nylon mesh in a recording chamber, and then perfused at a
rate of 10 ml⁄min with normal Krebs solution containing (in mM):
NaCl 117, KCl 3.6, CaCl2 2.5, MgCl2 1.2, Na2HPO4 1.2, NaHCO3 25,
glucose 11, at 36 ± 1 C for at least 1 h prior to recordings.
Electrophysiological recordings
The lamina II was clearly discernible as a relatively translucent band
across the dorsal horn under a dissecting microscope with transmitted
illumination. Blind whole-cell patch-clamp recordings were made
from SG neurons in voltage clamp mode using patch-pipette electrodes
with a resistance of 5–10 MX (Yoshimura & Nishi, 1993; Kohno
et al., 2003). Two pipette solutions were used. The ﬁrst solution
contained (in mm): potassium gluconate 135, KCl 5, CaCl2 0.5, MgCl2
2, EGTA 5, HEPES 5 and ATP-Mg 5 (pH 7.2). Guanosine-5¢-O-
(2-thiodiphosphate) (GDP-b-S, 2 mm) was used as a GTP-binding
protein blocker when necessary. The second solution contained
(in mm): Cs2SO4 110, tetraethylammonium (TEA) 5, CaCl2 0.5,
MgCl2 2, EGTA 5, HEPES 5 and ATP-Mg 5 (pH 7.2). Cs and TEA
were used as K
+ channel blockers. Membrane currents were ampliﬁed
using an Axopatch 200B ampliﬁer (Molecular Devices). Signals were
ﬁltered at 2 kHz and digitized at 5 kHz. Data were collected and
analysed using pClamp9.0 software (Molecular Devices).
Application of drugs
Drugs were applied by superfusion without alteration of the perfusion
rate or temperature. The drugs used were dexmedetomidine (provided
by Abbott Japan), prazosin, yohimbine, tetrodotoxin (TTX) (Wako,
Japan), oxymetazoline, GDP-b-S, acridin-9-yl-[4-(4-methylpiperazin-
1-yl)-phenyl]amine (JP-1302) (Sigma-Aldrich, USA), 2-[(4,5-dihydro-
1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate
(BRL44408) (Tocris Bioscience, USA).
Data analysis
Numerical data are expressed as means ± SEM. Statistical signiﬁ-
cance was assessed as P < 0.05 using the paired Student’s t-test. In all
cases, n refers to the number of neurons studied. Relative peak
amplitude was calculated as an amplitude of dexmedetomidine-
induced current in the presence of the drugs, divided by that of
currents produced by dexmedetomidine alone. The continuous curve
for the concentration–response relationship of dexmedetomidine
was drawn according to the following Hill equation:
y = 1.3⁄[1 + (EC50⁄x)
b], where x is the dexmedetomidine concentra-
tion and b is the Hill coefﬁcient.
Results
Dexmedetomidine induces currents in dorsal horn neurons
The resting membrane potentials in the SG neurons were
)65.8 ± 0.8 mV (n = 17). In 92% of the SG neurons examined
(n = 84), bath-applied dexmedetomidine induced outward currents at
)70 mV. As shown in Fig. 1A, outward currents exhibited a clear
dose-dependency on dexmedetomidine perfused at the surface of the
spinal cord. The onset of the responses became slow and recovery was
delayed with increasing concentrations of dexmedetomidine. Fig. 1B
shows a concentration–response curve of the dexmedetomidine-
induced outward currents. Analysis of the curve gave 0.62 lm as
the effective concentration producing a half-maximal response (EC50)
with a Hill coefﬁcient of 1.34. A higher concentration of dexmede-
tomidine produced a long duration at a holding potential of )70 mV
(Fig. 1A) and it was difﬁcult to be applied repeatedly. Consequently,
we used a low concentration of dexmedetomidine (0.03 lm) in order
to reproduce responses when it was repeatedly applied. In addition, the
dexmedetomidine (0.03 lm)-induced outward currents could not be
observed at a holding potential of )70 mV, as shown in Fig. 1B.
Therefore, we recorded the currents at a holding potential of )40 mV
(Fig. 1C and D). To conﬁrm that the dexmedetomidine-induced
currents were postsynaptic effects, we examined the currents in the
presence of TTX to remove any possible inﬂuence of a2-adrenoceptors
on presynaptic terminals. We compared peak amplitude elicited by
dexmedetomidine (0.03 lm) in the absence and presence of TTX
(1 lm). TTX had no signiﬁcant effect on the amplitude of dexmede-
tomidine (Fig. 1C and D, 96.2 ± 1.3% of control, P = 0.91, n = 5).
Pharmacological analysis of dexmedetomidine-induced
responses
We examined the effects on dexmedetomidine-induced responses of
the antagonists prazosin (2 lm) and yohimbine (4 lm), as compared
with those of previous studies (prazosin 0.5–2 lm, yohimbine
1–4 lm) (Baba et al., 2000; Kawasaki et al., 2003; Sonohata et al.,
2004). The dexmedetomidine-induced outward currents were attenu-
ated by the application of the a2-adrenoceptor antagonist yohimbine
(4 lm), while the a1-adrenoceptor antagonist prazosin (2 lm) had no
signiﬁcant effect (Fig. 2A). Figure 2B shows a summary of the
suppressive effects of each adrenergic antagonist. We next examined
the effects on dexmedetomidine-induced responses using a lower
concentration of prazosin (0.2 lm) and yohimbine (0.4 lm). How-
ever, these antagonists did not have any effect on the dexmedetom-
idine-induced outward currents (prazosin, 93.3 ± 4.1% of control,
P = 0.71; yohimbine, 91.0 ± 7.4% of control, P = 0.88, n = 5). These
results suggested that the dexmedetomidine-induced outward current
was mediated by a2-adrenoceptors.
Application of a high concentration of dexmedetomidine (3 lm)
produced an outward current of long duration. Superfusing yohimbine
(4 lm) alone accelerated the recovery of outward currents to baseline
level (Fig. 2C and D), conﬁrming that the dexmedetomidine-induced
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the involvement of a2A- and a2C-adrenoceptors on the dexmede-
tomidine-induced current, we used a2A- and a2C-adrenoceptor
subtype-preferring antagonists (Fig. 2E and F). Application of the
a2C-adrenoceptor antagonist JP-1302 (5 lm) partially suppressed the
dexmedetomidine (0.03 lm)-induced current. In addition, it was
markedly abolished when dexmedetomidine was again applied in the
presence of JP-1302 (5 lm) and the a2A-adrenoceptor antagonist
BRL44408 (5 lm). Relative peak amplitude was reduced to
3.3 ± 0.3 pA in the presence of JP-1302 and to 0.1 ± 0.1 pA in the
presence of JP-1302 plus BRL44408 (dexmedetomidine alone,
6.9 ± 0.6 pA, Fig. 2F). We next used oxymatazoline, an a2A-adreno-
ceptor agonist (Miyazaki et al., 1998; Kawasaki et al., 2003). In nine
of ten neurons, oxymatazoline (10 lm) induced an outward current
similar to that of dexmedetomidine (Fig. 2G) with a peak amplitude of
10.2 ± 1.0 pA (n = 9). This result suggested that a2A-adrenoceptors
Fig. 1. Dexmedetomidine induces an outward current in a concentration-dependent manner in SG neurons. (A) Outward currents induced by dexmedetomidine (0.1,
1 and 10 lm). Duration of drug superfusion is shown by horizontal bars above chart recordings. Holding potential = )70 mV. (B) Relative peak amplitude was
calculated as an amplitude of the dexmedetomidine (0.1–30 lm)-induced current divided by that of the current produced by dexmedetomidine (30 lm). The
continuous curve was drawn according to the Hill plot with an EC50 value of 0.62 lm (95% conﬁdence interval, 0.51–0.77 lm) and a Hill coefﬁcient of 1.34. The
number next to each point denotes the number of neurons examined. Holding potential = )70 mV. (C) Outward currents elicited by dexmedetomidine (0.03 lm)i n
the absence and presence of TTX (1 lm). These currents were obtained from the same neuron (n = 5). Holding potential = )40 mV. (D) Relative peak amplitude
was calculated as an amplitude of dexmedetomidine-induced current in the presence of TTX (5.3 ± 1.3 pA) divided by that of currents produced by
dexmedetomidine (5.6 ± 1.4 pA) without TTX.
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that both a2A- and a2C-adrenoceptors were involved in the dexmede-
tomidine-induced current.
Dexmedetomidine activates K
+ channels through the
activation of G-proteins on SG neurons
We next investigated what kinds of channels mediate the
dexmedetomidine current. Figure 3A shows the dexmedetomidine
(3 lm)-induced currents recorded at different holding potentials.
Plots of the current–voltage relationship revealed a reversal
potential at around )86 mV (Fig. 3B), which is slightly different
from the equilibrium potential ()97 mV) of K
+, as calculated from
the Nernst equation using K
+ concentrations ([K
+]o, 3.6 mm;[ K
+]i,
140 mm) of the solutions. This slight difference might be consid-
ered to reﬂect a liquid junction potential (9–10 mV) existing
between the Krebs and patch-pipette solutions (Yajiri et al., 1997).
Superfusing dexmedetomidine opens K
+ channels on postsynaptic
Fig. 2. Dexmedetomidine-induced currents are mediated by a2-( a2A- and a2C-) but not by a1-adrenoceptors. (A) Prazosin (2 lm), an a1-adrenoceptor antagonist,
did not affect the amplitude of the outward current induced by dexmedetomidine (0.03 lm), whereas the currents were suppressed by application of yohimbine
(4 lm), an a2-adrenoceptor antagonist. These currents were obtained from the same neuron (n = 6). Holding potential = )40 mV. (B) Relative peak amplitude was
calculated as an amplitude of dexmedetomidine-induced current in the presence of prazosin (8.7 ± 2.2 pA) or yohimbine (0.1 ± 0.1 pA) divided by that of currents
produced by dexmedetomidine (9.3 ± 2.6 pA) alone. *P < 0.05, control vs. yohimbine. Holding potential = )40 mV. (C) Dexmedetomidine (3 lm) produced an
outward current of long duration. A persistent outward current after washout of dexmedetomidine was completely reduced in amplitude by yohimbine (4 lm).
Holding potential = )40 mV. (D) The dexmedetomidine-induced outward currents in the presence of yohimbine were signiﬁcantly smaller than control (*P < 0.05,
n = 10). (E) Application of JP-1302 (5 lm) partially blocked the dexmedetomidine (0.03 lm)-induced current, and simultaneous application of JP-1302 (5 lm) and
BRL44408 (5 lm) abolished the current completely. These currents were obtained from the same neuron (n = 6). Holding potential = )40 mV. (F) Relative peak
amplitude was calculated as an amplitude of dexmedetomidine-induced current in the presence of JP-1302 (3.3 ± 0.3 pA) or JP-1302 plus BRL44408 (0.1 ± 0.1 pA)
divided by that of currents produced by dexmedetomidine (6.9 ± 0.6 pA) alone. *P < 0.05, control vs. JP-1302.
#P < 0.05, control vs. JP-1302 plus BRL44408. (G)
Dexmedetomidine-induced outward current was mimicked by the a2A-adrenoceptor agonist oxymetazoline (10 lm) on SG neurons. Holding potential = )40 mV.
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below )90 mV.
To determine whether G-proteins are responsible for the dexmede-
tomidine-induced current, GDP-b-S (2 mm), a non-hydrolysable
analog of GDP that competitively inhibits G-proteins, was used in
the pipette solution to prevent the postsynaptic activation of
a2-adrenoceptors. When dexmedetomidine (3 lm) was applied shortly
after establishing the whole-cell conﬁguration, an outward current was
observed (Fig. 4A). This outward current was completely abolished
when dexmedetomidine was again applied 15 min later (Fig. 4A,
n = 5). We next used the pipette solution containing Cs
+ and TEA to
inhibit the postsynaptic effect of K
+ channels. Dexmedetomidine
(3 lm)-induced outward current was recorded just after establishing
the whole-cell conﬁguration (Fig. 4B). However, this current was
abolished after the second application of dexmedetomidine, which was
performed more than 5 min later (Fig. 4B, n = 7). These ﬁndings
Fig. 3. (A) Dexmedetomidine-induced currents show voltage dependency. (B) Relationship between holding potential and current amplitude. The regression
equation was y = 0.901x + 77.1 [R
2 = 0.92, P = 0.002, y = amplitude of current (pA), x = holding potential (mV)].
Fig. 4. Inhibition of dexmedetomidine-induced current by GDP-b-S or Cs
+ ⁄ TEA. (A) The dexmedetomidine (3 lm)-induced outward current was examined with
K-gluconate pipette solution containing GDP-b-S (2 mm). Dexmedetomidine produced an outward current just after establishing the whole-cell conﬁguration, but
this was markedly abolished when dexmedetomidine was again applied 15 min later (*P < 0.05, n = 5). Holding potential = )40 mV. (B) Dexmedetomidine (3 lm)
induced an outward current just after establishing whole-cell recording with Cs
+ and TEA-containing pipette. When dexmedetomidine was again applied 5 min later,
the current was completely abolished (n = 7). Holding potential = )40 mV.
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mediated by K
+ channels through the activation of G-proteins.
Effects of dexmedetomidine on spontaneous excitatory
postsynaptic currents
We next examined the effects of dexmedetomidine on spontaneous
excitatory postsynaptic currents (sEPSCs) in SG neurons (Fig. 5A).
Amplitude and inter-event interval distributions were not changed by
dexmedetomidine (Fig. 5B; amplitude, P > 0.05, Kolmogorov–Smir-
nov test; inter-event interval, P > 0.05). These data indicate that
dexmedetomidine does not affect glutamate release from presynaptic
terminals.
Discussion
Intrathecal dexmedetomidine is a highly potent antinociceptive agent
in animals (Fisher et al., 1991). Lipophilicity may affect the analgesic
potency of intrathecally administered agents (Eisenach et al., 1994).
Highly lipophilic agents bind to spinal cord more efﬁciently than
poorly lipophilic drugs. Dexmedetomidine is more lipophilic than
clonidine (Savola et al., 1986). Eisenach et al. (1994) showed that
intrathecal administration of dexmedetomidine at a dose of 100 lg
produced an antinociceptive effect that was ﬁrst evident at 30 min and
lasted for 90 min after the injection. As these authors demonstrated in
a separate set of experiments in the same study, intrathecal admin-
istration of dexmedetomidine at this dose resulted in cerebrospinal
ﬂuid concentrations ranging from 300 to 3000 ng⁄ml (nearly
1–10 lm) during the period 30–90 min after injection. These results
are consistent with the concentrations of dexmedetomidine that
induced outward currents in the present study (Fig. 1B). Taken
together, these data suggest that the cerebrospinal ﬂuid concentration
of dexmedetomidine required for antinociception is 1–10 lm.
Behavioral studies in rats have demonstrated that intrathecal
administration of dexmedetomidine produces dose-dependent antino-
ciception (Fisher et al., 1991). Low doses of dexmedetomidine
produced a transient period of antinociception. On the other hand,
profound antinociception was prolonged by high doses of dexmede-
Fig. 5. Dexmedetomidine dose not affect the frequency or amplitude of spontaneous EPSCs in SG neurons. (A) Continuous chart recording of sEPSCs before and
during the application of dexmedetomidine (3 lm) (upper trace). Four consecutive traces of sEPSCs for a period indicated by a short bar below the chart recording
are shown on an expanded time scale (lower traces). Holding potential = )70 mV. (B) Cumulative distributions of the amplitude (left) and the inter-event interval
(right) of sEPSCs before (dashed line) and during the application of dexmedetomidine (continuous line). Dexmedetomidine had no signiﬁcant effect on the amplitude
(P > 0.05; Kolmogorov–Smirnov test) or the inter-event interval distribution (P > 0.05).
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concentration of dexmedetomidine (0.03 lm) in the present study
(Fig. 2A). By contrast, a high concentration of dexmedetomidine
(3 lm) produced a current with a long duration (Fig. 2C). The
durations of dexmedetomidine (3 lm)-induced currents were longer
than 30 min in most neurons without desensitization. The higher the
concentration of dexmedetomidine, the longer the duration tended to
be. The durations of dexmedetomidine-induced outward currents were
much longer than those induced by noradrenaline (Sonohata et al.,
2004). This long duration may be caused by the high afﬁnity of
dexmedetomidine. A radioligand binding study showed that the
binding afﬁnity (pKi) value of dexmedetomidine was higher than that
of noradrenaline for the a2-adrenoceptor (Jasper et al., 1998).
Alternatively, the long-term effect may be due to a slow rate of
diffusion of dexmedetomidine out of the spinal cord slice (Koga et al.,
2005). This issue remains to be established.
As mentioned above, superﬁcial dorsal horn neurons are important
for processing nociceptive information from primary afferent ﬁbers.
Binding and immunohistochemical studies have suggested that the
highest density of a2-adrenoceptors exist in the superﬁcial layers of
the spinal dorsal horn (Roudet et al., 1994; Stone et al., 1998). In
addition, the binding sites of the a2A-adrenoceptors in the superﬁcial
dorsal horn were dramatically reduced in number after neonatal
capsaicin treatment or dorsal rhizotomy, whereas a2C-adrenoceptors
were not signiﬁcantly reduced by either of these treatments. This
ﬁnding suggests that a2C-adrenoceptors exist in postsynaptic sites
(Stone et al., 1998; Olave & Maxwell, 2002), and that a2A-
adrenoceptors are located mainly in presynaptic sites (Stone et al.,
1998; Kawasaki et al., 2003) of the dorsal horn. By contrast, few a2B-
adrenoceptors were seen in the spinal dorsal horn by in situ
hybridization studies of the distribution of a2B mRNA (Nicholas
et al., 1993; Shi et al., 1999). Furthermore, an a2-adrenoceptor agonist
did not change spinal antinociception in a2B-adrenoceptor knockout
mice, suggesting that a2B-adrenoceptors do not participate in the
antinociceptive effect in the spinal cord (Fairbanks et al., 2002).
However, these immunohistochemical studies showed a dramatic, but
incomplete, reduction in a2A-adrenoceptor immunoreactivity. This
result raised the question of whether a2A-adrenoceptors were also
located on postsynaptic SG neurons, in addition to a2C-adrenoceptors.
We used prazosin as the a1-adrenoceptor antagonist, but prazosin acts
not only as an a1-adrenoceptor, but also has some properties of
a2B- and a2C-adrenoceptor antagonists (Bylund, 1988; MacDonald
et al., 1997). The binding inhibition coefﬁcients (Ki) of prazosin were
2750, 108 and 98 nm for the a2A-, a2B- and a2C-adrenoceptor,
respectively (Marjamaki et al., 1993). Nevertheless, our study showed
that dexmedetomidine-induced currents were not blocked by the
a2B- and a2C-adrenoceptor antagonistic action of prazosin in SG
neurons (Fig. 2A and B). Therefore, highly selective a2A-o r
a2C-adrenoceptor antagonists were superfused to investigate this
question. BRL44408 was noted as a selective a2A-adrenoceptor
antagonist having Ki of 4, 174 and 187 nm for the a2A-, a2B- and
a2C-adrenoceptor, respectively (Bylund et al., 1994). JP-1302 was
recently described as a novel, highly selective a2C-adrenoceptor
antagonist (Sallinen et al., 2007). The Ki were 1500, 2200 and 16 nm
for the a2A-, a2B- and a2C-adrenoceptor, respectively. Application of
JP-1302 partially suppressed the dexmedetomidine-induced current,
and simultaneous application of JP-1302 and BRL44408 abolished the
amplitude of the current completely (Fig. 2E and F). Our ﬁndings
clarify the involvement of both a2A- and a2C-adrenoceptors in the
dexmedetomidine-induced current. Furthermore, we showed that the
dexmedetomidine-induced current seen in postsynaptic SG neurons
was mimicked by oxymetazoline, an a2A-adrenoceptor agonist
(Fig. 2G). The Ki were 6, 3150 and 180 nm for the a2A-, a2B- and
a2C-adrenoceptor, respectively (Marjamaki et al., 1993). Taking these
data together, it is likely that dexmedetomidine activates both a2A- and
a2C-adrenoceptors on postsynaptic SG neurons and induces currents.
As we did not examine the application of an a2C-adrenoceptor agonist,
we could not conclude whether there were a2C-adrenoceptors in
postsynaptic SG neurons. Further studies are required with highly
selective a2A-o ra2C-adrenoceptor agonists and antagonists.
We showed that activation of a2-adrenoceptors with dexmedetom-
idine resulted in outward currents that were mediated by activation of
K
+ channels through the activation of G-proteins (Figs 3 and 4). These
ﬁndings suggest that dexmedetomidine hyperpolarizes the membrane
potentials of SG neurons by opening G-protein-coupled inwardly
rectifying potassium (GIRK) channels. The GIRK1 and GIRK2
subunits are concentrated in lamina II of the mouse spinal cord
(Marker et al., 2005). As the antinociceptive effect of clonidine was
reduced in GIRK2-knockout mice (Mitrovic et al., 2003), it is possible
that dexmedetomidine exerts its effects on GIRK channels similarly to
clonidine.
We focussed on the postsynaptic effects of dexmedetomidine in
SG neurons. However, a2-adrenoceptors are also localized on
primary afferent terminals (Stone et al., 1998). Noradrenaline acts
on a2-adrenoceptors on postsynaptic (Sonohata et al., 2004) and
presynaptic (Kawasaki et al., 2003) SG neurons, and produces an
antinociceptive effect. Kawasaki et al. (2003) showed that nor-
adrenaline, clonidine and oxymetazoline inhibited the peak ampli-
tudes of monosynaptically evoked Ad- and C-ﬁber EPSCs, while
miniature EPSC (mEPSC) amplitude and frequency was unaffected
by noradrenaline. Pan et al. (2002) reported that the peak amplitude
of evoked EPSCs was attenuated by clonidine in the outer zone of
SG. Furthermore, clonidine signiﬁcantly decreased the frequency of
mEPSCs. A discrepancy between this and the current study may be
due to the fact that different SG neurons were tested; Pan et al.
examined neurons in the outer layer of SG, while we investigated
neurons located at the center of SG. The possibility cannot be ruled
out that SG neurons exhibiting no effect of noradrenaline on
mEPSCs (Kawasaki et al., 2003) or no effect of dexmedetomidine
on sEPSCs in the current study (where the blind patch-clamp
technique was used) had located in the inner layer of SG because
visually identiﬁed neurons in the inner layer of SG appeared to be
without actions of clonidine on mEPSCs (Pan et al., 2002). Li &
Zhuo (2001) showed that clonidine inhibited glutamate-mediated
evoked EPSCs. However, clonidine preferentially depressed poly-
synaptic but not monosynaptic Ad-ﬁber-evoked ﬁeld potentials in
superﬁcial spinal dorsal horn (Ruscheweyh & Sandkuhler, 2000).
Moreover, a2-adrenoceptor agonists depressed the NMDA receptor-
mediated excitatory postsynaptic potential on A- and C-primary
afferent ﬁbers (Faber et al., 1998). Our results showed that
dexmedetomidine did not affect glutamate release from presynaptic
terminals. Whether dexmedetomidine exhibits a similar presynaptic
action on these currents needs to be established.
In conclusion, the present study suggests that dexmedetomidine
hyperpolarizes the membrane potentials of spinal dorsal horn neurons
via G-protein-mediated activation of K
+ channels through a2-adreno-
ceptors. This action of dexmedetomidine might contribute, at least in
part, to its antinociceptive action in the spinal cord.
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